GLPwatch
Long-acting preparations of exenatide.
Drug Des Devel Ther · 2013
Last updated 2026-05-28Exenatide is a medication used to treat type 2 diabetes, but its effects last only about 2.4 hours in the body, which limits its use. Currently, it is available as a twice-daily injection (Byetta) or a once-weekly injection (Bydureon). Researchers are exploring ways to extend its effects through new long-acting forms.
AI summary of the abstract below.
| Journal | Drug Des Devel Ther, 2013 |
|---|---|
| Citations | 45 |
| Relative citation ratio | 1.68 |
| NIH percentile | 68 |
| Molecules | exenatide |
| Conditions studied | Type 2 Diabetes |
Abstract
Exenatide has been widely used for the treatment of type 2 diabetes mellitus. However, its short plasma half-life of 2.4 hours has limited its clinical application. The exenatide products on the market, twice-daily Byetta™ and once-weekly Bydureon™ (both Amylin Pharmaceuticals, San Diego, CA, USA), are still not perfect. Many researchers have attempted to prolong the acting time of exenatide by preparing sustained-release dosage forms, modifying its structure, gene therapies, and other means. This review summarizes recent advances in long-acting exenatide preparations.
Verbatim abstract via PubMed 24039406 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.